Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04908059
Other study ID # 8115
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 27, 2021
Est. completion date July 13, 2021

Study information

Verified date May 2021
Source University Hospital, Strasbourg, France
Contact Laurent MAUVIEUX, MD, PhD
Phone 33 3 88 12 75 27
Email laurent.mauvieux@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL


Recruitment information / eligibility

Status Recruiting
Enrollment 2
Est. completion date July 13, 2021
Est. primary completion date July 13, 2021
Accepts healthy volunteers No
Gender All
Age group 9 Years and older
Eligibility Inclusion Criteria: - Patients presenting a leukemic phase of anaplastic lymphoma Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Hematology Laboratory - Strasbourg University Hospitals Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary A retrospective study of the diagnostic description of the leukemic phases of anaplastic lymphoma in real life Files analysed retrospectively from January 01, 2020 to December 31, 2020 will be examined]
See also
  Status Clinical Trial Phase
Recruiting NCT03971305 - A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
Suspended NCT04828174 - Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies Phase 1